Lady Prelox®-Studies
Effects of Lady Prelox® on climacteric symptoms and sexual function in 80 peri-menopausal women aged 40-50 years
Stanislavov et al. 2014
Aim
The aim of this study was to evaluate Lady Prelox®, a dietary supplement for climacteric symptoms and sexual function in peri-menopausal women, in a double-blind, placebo-controlled manner.
Methods
The study included sexual women aged 40-50 years who presented to the university hospital with both moderate sexual dysfunction and menopausal symptoms. Following medical examination, eligible women were randomly assigned to either the Lady Prelox® group or placebo for eight weeks. Menopausal symptoms were described using the established Women's Health Questionnaire and Kupperman's menopause rating scale. Women's sexual function was examined using the female sexual function index (FSFI).
Results
In placebo-treated women, the total FSFI score did not increase significantly from a baseline of 12.4 ± 2.3 to 14.4 ± 2.8 after four weeks and from 16.6 ± 2.3 after eight weeks. The FSFI score was higher at baseline in the Lady Prelox® group than in the placebo group (16.5 ± 2.9) and improved to 21.7 ± 2.8 and 26.5 ± 3.3 after four and eight weeks, respectively. Lady Prelox® scores after four and eight weeks of treatment were statistically significantly higher than in the placebo group. A detailed examination of the different domains of the FSFI shows that Lady Prelox® significantly improved all “desire”, “arousal”, “orgasm”, “satisfaction” and “pain”. Comparatively, the areas of “orgasm” and “satisfaction” were found to have improved most significantly.
Climacteric symptoms were significantly improved with Lady Prelox® after four and eight weeks of treatment. A group of symptoms, including hot flashes, night sweats, sleep problems, irritability, depressed mood and mental focus, were found to be significantly improved after four weeks compared with women taking placebo. These improvements were maintained until the study was completed after eight weeks. All symptoms except “depressions” of the “Women’s Health Questionnaire” were less pronounced than in the placebo group. Symptoms that responded particularly well to Lady Prelox® were related to cognition (mental focus) and “anxiety/fear”. Interestingly, the symptom most affected by placebo administration was self-perceived attraction. Safety assessments indicate that Lady Prelox® and placebo were well tolerated and no side effects were observed in any of the subjects. Blood laboratory tests confirm the safety of the product. After eight weeks, a small but statistically significant decrease in systolic and diastolic blood pressure was seen with Lady Prelox®. Blood pressure, BMI, lipid profile and TAC were significantly improved in the Lady Prelox® group.
This study demonstrates promising overall improvement for women during the difficult transition of menopause. The simultaneous improvement of both sexual and climacteric symptoms requires further investigation to define long-term benefits.
Post-menopausal women
Lady Prelox® helps improve sexual function in postmenopausal women
Bottari A et al., Panminerva Med 2012
Aim
The aim of this pilot registration study was to evaluate the efficacy of Lady Prelox® to improve/control sexual dysfunction (SD) in postmenopausal women with a healthy circulation.
Methods
Lady Prelox® and control groups were compared with respect to Female Sexual Function Index (FSFI) score in 36 women (50.1 ± 3.1 years) and 39 women (51.2 ± 2.3 years), respectively.
After four weeks of treatment, there was significant improvement in the group that continued until completion of the eight-week trial. Small, nonsignificant changes were observed in controls.
The median FSFI score included was 44.6 and increased significantly to 70.9 after four weeks and remained at this level after eight weeks.
In the control group, total FSFI increased from 44.1 at inclusion to 45.0 after four weeks and 47.4 after eight weeks. Treatment with Lady Prelox® was comparatively more effective than placebo.
Conclusion
This study provides an interesting perspective for women suffering from sexual dysfunction and offers a promising new treatment option.
Women in their reproductive years
Lady Prelox® supports sexual function in generally healthy women during their reproductive years.
Belcaro et al., Minerva Ginecologica 2013
Aim
The aim of this study was to evaluate the effects of Lady Prelox® on improving sexual function in healthy women presenting with moderate symptoms of sexual dysfunction.
Methods
The women investigated in this study were between the ages of 37 and 45, none had gone through menopause and all were in general health. The Lady Prelox® and placebo treated groups were assessed by the short form of the Female Sexual Function Index (FSFI) score in 49 women (40.4 ± 2.3 years) and 51 women (41.3 ± 2.2 years). The women were treated with Lady Prelox® or placebo tablets of the same appearance for eight weeks.
Results
In placebo-treated women, the FSFI score did not significantly increase from 17.9 ± 2.3 at baseline to 23.5 ± 1.8 after four weeks and from 23.5 ± 2.2 after trial completion after eight weeks. The Lady Prelox®-treated group of women presented with a mean baseline FSFI score of 15.0 ± 2.7, increasing to 28.3 ± 2.4 after four weeks of treatment and reaching 33.9 ± 2.7 after eight weeks. The scores observed in the Lady Prelox®-treated group were statistically significant versus the placebo group and baseline values at both time points, four and eight weeks, respectively.
Conclusion
All areas of the female sexual function score, particularly the categories of “dryness,” “sexual desire,” and “satisfaction” related to “sexual satisfaction in intercourse,” showed improvements with Lady Prelox®. Lady Prelox® and the corresponding placebo were well tolerated and women did not experience significant side effects attributable to the study tablets.
